Trials / Unknown
UnknownNCT04634747
Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembrolizumab + Chemotherapy for Frontline Therapy of Metastatic, PD-L1+ Triple-Negative Breast Cancer (TNBC) in HLA-A2-Positive Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- Sponsor
- OncoPep, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating the combination of the investigational, multi-peptide cancer vaccine PVX-410 in combination with pembrolizumab and chemotherapy in treatment naive patients with metastatic, triple negative breast cancer who are PDL1 and HLA A2 positive.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PVX-410 | PVX-410 in combination with pembrolizumab and chemotherapy |
Timeline
- Start date
- 2022-04-30
- Primary completion
- 2023-04-01
- Completion
- 2025-04-01
- First posted
- 2020-11-18
- Last updated
- 2022-04-20
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04634747. Inclusion in this directory is not an endorsement.